CARDIOL THERAPEUTICS INC-A (CRDL.CA) Stock Analyst Ratings
Canada - TSX:CRDL - CA14161Y2006 - Common Stock
1.51 CAD
+0.03 (+2.03%)
ChartMill assigns a Buy % Consensus number of 83% to CRDL.CA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 11.22. This target is 643.05% above the current price.
CRDL.CA was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about CRDL.CA.
In the previous month the buy percentage consensus was at a similar level.
CRDL.CA was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-11-08 | Raymond James Capital | Downgrade | Market Perform |
| 2022-09-01 | Raymond James Capital | Downgrade | Market Perform |
| 2022-04-18 | Canaccord Capital | Reiterate | Buy |
| 2022-03-17 | Raymond James Capital | Downgrade | Market Perform |
| 2022-02-04 | Raymond James Financial | Initiate | Outperform |
| 2021-11-11 | RaymondJamesFinancial | Initiate | Outperform |
| 2021-08-25 | Raymond James Financial | Upgrade | Outperform |
| 2021-05-19 | ATB Catpital | Downgrade | Speculative Buy |
| 2021-05-19 | ATB Capital | Downgrade | |
| 2021-05-17 | Raymond James Financial | Upgrade | Outperform |
| 2021-04-29 | Raymond James Financial | Upgrade | Market Perform -> Outperform |
| 2021-04-14 | Raymond James Financial | Reiterate | Market Perform |
| 2021-04-05 | ATB Capital | Downgrade | Speculative Buy |
| 2021-03-04 | Raymond James Financial | Initiate | Market Perform |